Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? Balasubramanian P, Wanner C, Ferreira JP, Ofstad AP, et al. J Clin Endocrinol Metab 2022;107:e3003-e3007.

Read + Share

Amedeo Smart

Independent Medical Education

Balasubramanian P, Wanner C, Ferreira JP, Ofstad AP, et al. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? J Clin Endocrinol Metab 2022;107:e3003-e3007.
PMID: 35290464